Blueprint Medicines Corporation (2L9.F)

100,30 +2,28 (+2,33 %) À la clôture : 03:50PM CEST

Blueprint Medicines Corporation

45 Sidney Street
Cambridge, MA 02139
United States
617 374 7580
https://www.blueprintmedicines.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 645

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Ms. Kathryn Haviland	President, CEO & Director	1,41M	S.O.	1976
Mr. Alexis A. Borisy A.M.	Co-Founder & Director	46,51k	S.O.	1972
Mr. Michael Landsittel	Chief Financial Officer	820,34k	S.O.	1972
Ms. Christina Rossi M.B.A.	Chief Operating Officer	1,03M	S.O.	1976
Dr. Percy H. Carter M.B.A., Ph.D.	Chief Scientific Officer	918,01k	S.O.	1971
Dr. Fouad Namouni M.D.	President of Research & Development	1,02M	S.O.	1969
Ms. Ariel Hurley	Senior VP, Finance & Principal Accounting Officer	S.O.	S.O.	1974
Dr. Christopher K. Murray Ph.D.	Chief Technical Operations & Quality Officer	314,76k	S.O.	1963
Jenna Cohen	Senior Director & Head of Investor Relations	S.O.	S.O.	S.O.
Ms. Tracey L. McCain Esq.	Executive VP, Chief Legal & Compliance Officer and Secretary	711,54k	S.O.	1968

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Blueprint Medicines Corporation en date du 1 mai 2024 est 6. Les scores principaux sont Audit : 2; Société : 8; Droits des actionnaires : 7; Compensation : 6.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.